Skip to content
Molecules
SEKISUI XenoTech DD Blog Logo

Maximize Metabolic Activities by Limiting Hepatocyte Cryoinjury

Cryopreservation and thawing of primary hepatocytes causes inherent damage to the cells. Traditional pooling methods require cells to undergo two separate cryopreservation and thaw steps, leading to increased cryoinjury and decreased metabolic activity.

CryostaX® hepatocytes use a patented process that allows scientists to create primary hepatocyte pools from up to 20 donors with only a single cryopreservation. Individual donor hepatocytes are cryopreserved as CryostaX® pellets, which can then be physically combined and packaged into a single vial without having to thaw and re-cryopreserve a second time. This limits the cryoinjury to each donor, maximizing the metabolic activity of the pool, and removes the extra cost usually associated with custom pooling.

Data indicates that minimizing cryoinjury leads to a modest conservation of CYP450 and SULT activities, but has significant advantages when examining UGT activity. When choosing suspension or attaching hepatocytes for your experiments, why choose pools with increased cryoinjury?

Learn more about our patented CryostaX® technology
View available cryopreserved hepatocytes
Contact us with any questions or requests

Fig. 1 – The effects of multiple freezes on the activity of phase-1 and phase-2 enzymes in human hepatocytes: Average of four donors frozen and refrozen individually

Fig. 2 – The effects of multiple freezes on the activity of phase-1 and phase-2 enzymes in human hepatocytes (pools contain cells from the same donors)

CryostaX Hepatocytes

Fig. 3 – The effects of multiple freezes on the activity of UDP-glucuronosyl transferases in human hepatocytes (pools contain cells from the same donors)

CryostaX Hepatocytes Metabolic

About the Authors

Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing SEKISUI XenoTech’s scientific expertise and knowledge with scientists around the world.
Dr. Chris Bohl received his PhD from the School of Biological Sciences from the University of Nebraska – Lincoln and has been with SEKISUI XenoTech since 2014, first operating as a research scientist before becoming the Senior Manager of Technical Support for Products. Chris provides valuable guidance to scientists seeking to choose the correct test system, troubleshoot difficulties and much more.

Subscribe to our Newsletter

Stay up to date with our news, events and research

In vitro pipette test article treatment
005 International Messaging Created with Sketch.

Do you have a question or a request for upcoming blog content?

We love to get your feedback

A scientist utlilizing a microplate